A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This Phase 3, open-label, triple arm study aims to evaluate the overall survival (OS) of fotemustine versus the combination of ipilimumab and fotemustine or the combination of Ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis.
Epistemonikos ID: 912a59654fc2459f1414aaa7b3581692ad9bb1cc
First added on: May 12, 2024